Selzentry Patient Population Needs Further Definition, Advisory Panel Urges
Executive Summary
Determining the effect of Pfizer's Selzentry (maraviroc) in subpopulations of HIV patients was the theme of recommendations by the Antiviral Drugs Advisory Committee for post-marketing studies Oct. 8
You may also be interested in...
FDA Expands Selzentry Indication, But Ties Use To Screening With "Highly Sensitive" Assay
Labeling for additional indication for newly diagnosed patients cautions about higher virologic failure in treatment-naïve patients receiving maraviroc during the clinical trial.
FDA Expands Selzentry Indication, But Ties Use To Screening With "Highly Sensitive" Assay
Labeling for additional indication for newly diagnosed patients cautions about higher virologic failure in treatment-naïve patients receiving maraviroc during the clinical trial.
Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events
Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.